Michael R. Burgess

Bristol-Myers Squibb (United States) — United States

Medicine · Health Sciences

19h-index1.7kcitations51works3.22yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(17), Multiple Myeloma Research and Treatments(14), Acute Myeloid Leukemia Research(13), Chronic Lymphocytic Leukemia Research(10), Protein Degradation and Inhibitors(6)

Publications51 total

Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study
Leukemia·2026Open Access
Acute Myeloid Leukemia Relapse after Bromodomain Inhibitor Treatment or Chemotherapy is Characterized by Myc-Ras Transcriptional Remodeling
2025
Assessment of pharmacodynamic efficacy biomarkers from A phase 1, first-in-human study of arlocabtagene autoleucel (arlo-cel) in relapsed and refractory multiple myeloma (RRMM)
Blood·2025Open Access
Arlocabtagene Autoleucel, a GPRC5D-Targeted CAR T-Cell Therapy for Patients With Relapsed/Refractory Multiple Myeloma: Updated Phase 1 Safety and Efficacy Results in Patients With 1–3 Prior Regimens
Clinical Lymphoma Myeloma & Leukemia·2025
Long-term Follow-Up of a Phase 1 Study of Arlocabtagene Autoleucel (arlo-cel; BMS-986393) in Patients With Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM)
Clinical Lymphoma Myeloma & Leukemia·2025
Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma
Leukemia·2025· 3 citedOpen Access
Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Heavily Pretreated Relapsed/Refractory (RR) Multiple Myeloma (MM)
Blood·2024· 20 cited
BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1-3 Prior Regimens: Updated Phase 1 Safety and Efficacy Results
Blood·2024· 5 citedOpen Access
OA-08 Safety and Preliminary Efficacy of BMS-986393, a GPRC5D CAR T Cell Therapy, in Patients (pts) With Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1–3 Prior Regimens: Results From a Phase 1 Study
Clinical Lymphoma Myeloma & Leukemia·2024
Informing the Recommended Phase III Dose of Alnuctamab, a <scp>CD3</scp> × <scp>BCMA</scp> T‐Cell Engager, Using Population Pharmacokinetics and Exposure–Response Analysis
Clinical Pharmacology & Therapeutics·2024· 4 cited
BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study
Blood·2023· 55 cited
Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study
Blood·2023· 31 cited
P-037 BMS-986393 (CC-95266), a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted CAR T-cell therapy for relapsed/refractory multiple myeloma (RRMM): results from a phase 1 study
Clinical Lymphoma Myeloma & Leukemia·2023
P825: SOLUBLE FACTORS CORRELATED WITH CYTOKINE RELEASE SYNDROME (CRS) WITH IV VS SUBCUTANEOUS (SC) ALNUCTAMAB (ALNUC; BMS-986349; CC-93269) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
HemaSphere·2023Open Access
S193: BMS-986393 (CC-95266), A G PROTEIN–COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D (GPRC5D)–TARGETED CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1 STUDY
HemaSphere·2023· 15 citedOpen Access
P883: ALNUCTAMAB (ALNUC; BMS-986349; CC-93269), A BCMA × CD3 T-CELL ENGAGER, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): LATEST RESULTS FROM A PHASE 1 FIRST-IN-HUMAN CLINICAL STUDY
HemaSphere·2023· 14 citedOpen Access
Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study
Blood·2022· 39 cited
Soluble Factors Correlated with High-Grade Cytokine Release Syndrome (CRS): A Comparison of Subcutaneous (SC) Versus Intravenous (IV) Delivery of Alnuctamab (ALNUC; BMS-986349; CC-93269) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Blood·2022· 5 cited
Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Blood·2022· 37 cited
Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study
Blood·2022· 67 cited
page 1 of 3Next →

Frequent Co-authors

Luciano J. Costa(17), Kevin Shannon(14), Omar Nadeem(10), Safiyyah Ziyad(10), Allison Kaeding(10), Jesús G. Berdeja(10), Kristen Hege(9), Susan Bal(9), Larry D. Anderson(9), Tara Gregory(9), Hongxiang Hu(9), Qing Li(8), Allison Gaudy(8), Isaac W. Boss(7), Colin D. Godwin(7), Wei-Ming Kao(7), Charles L. Sawyers(6), Eugene Hwang(6), Daniel J. DeAngelo(6), Adriana Rossi(6)